Atara Biotherapeutics, Inc. · NASDAQ:ATRA
Atara Biotherapeutics — Q3 2024 Earnings Presentation
32 slides from Atara Biotherapeutics's earnings presentation, Nov 12, 2024
Slide 1: Investor Presentation Q3 2024
INVESTOR PRESENTATION Q3 2024 NOV 12, 2024 Nasdaq: ATRA 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prese
Slide 3: Atara is the first to deliver on the transformative potential of allogeneic T-cell therapy
ATARA IS THE FIRST TO DELIVER ON THE TRANSFORMATIVE POTENTIAL OF ALLOGENEIC T-CELL THERAPY First Company to Obtain Regulatory Approval for an Allogeneic T-cell Immunotherapy Tab-cel ® U.S. BLA On-track with Priority Review and Jan 15, 2025 PDUFA date EbvalloTM approved by EMA in December 2022 Near-T
Slide 4: Differentiated Allogeneic T-Cell Immunotherapy Pipeline
Differentiated Allogeneic T-Cell Immunotherapy Pipeline Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Registration Next Milestone ATA3219 Q1 2025: Initial NHL Ph 1 Non-Hodgkin’s Lymphoma (NHL) CD19 (Oncology) clinical data expected Lupus Nephritis (LN) Mid-2025: Initial LN Ph 1 clini
Slide 5: Atara Is the Most Advanced Allogeneic Cell Therapy Company
Atara Is the Most Advanced Allogeneic Cell Therapy Company Differentiated Based on natural biology of EBV T cells Platform First and only approved allogeneic T-cell therapy with EbvalloTM First allogeneic T-cell therapy BLA under review by FDA Supportive Robust allogeneic T-cell experience with favo
Slide 6: Innovating Next-Gen CAR T Leveraging the Only Allogeneic T-cell Platform With an Approved Product
Innovating Next-Gen CAR T Leveraging the Only Allogeneic T-cell Platform With an Approved Product Allogeneic EBV T-Cell (EBVALLOTM) Next-gen Allogeneic CAR T EBV TCR Chimeric Antigen Receptor CAR EBV TCR Manufacturing Viral Vector Healthy Donor Cells EBV T Cell EBV CAR T Cell No gene editing of th
Slide 7: Atara's Allogeneic CAR T Platform Designed to Improve Patient Journey and Expand Access
Atara’s Allogeneic CAR T Platform Designed to Improve Patient Journey and Expand Access Versus Autologous Cell Therapies Current Autologous CAR T Patient Journey Apheresis Lymphodepletion CAR T Treatment Post Infusion Monitoring • Time consuming, extra • Chemotherapy side effects • 2-5 weeks-long pr
Slide 8: Atara's CAR T Platform Closely Retains Autologous T-Cell Biology
Atara’s CAR T Platform Closely Retains Autologous T-Cell Biology While Offering the Benefits of an Allogeneic Approach Atara’sAtara’s Allogeneic CAR T Platform CAR Platform Addressing Key Challenges EBV Challenge: Graft vs Host Disease (GvHD) and Allorejection Specificity Atara Approach: Retained Re
Slide 9: Atara's CAR T Platform Offers Unique Advantages Versus Other Allogeneic Approaches
Atara’s CAR T Platform Offers Unique Advantages Versus Other Allogeneic Approaches in the Field Other Allogeneic CAR Platforms αβ T cell NK cell γδ T cell Atara Gene edited EBV CAR αβ T Cell NK Cell γδ T Cell T Cell Gene edited αβ TCR γδ TCR (αβ unedited) 600+ patients Safety safely treated3 Lower C
Slide 10: Novel 1XX Signaling Domain Proof of Concept in Both Oncology and Lupus Models
Novel 1XX Signaling Domain Proof of Concept in Both Oncology and Lupus Models 1XX Rationale and Design 1XX Pre-Clinical Proof Points Challenge: Signaling via CD28 and CD3ζ domains CAR T CAR T Oncology: CD28 1XX overstimulate T cells, leading to exhaustion; 4-1BB slower to activate1 Rapid tumor (aver
Slide 11: Reinforce Key Features of Atara's CAR T Platform in Oncology and Autoimmune Diseases
Clinical CAR T Data From Industry Leaders and Academia Reinforce Key Features of Atara’s CAR T Platform in Oncology and Autoimmune Diseases EBV Specific TCR & Less Differentiated 1XX Signaling Domain Retained MHC with Phenotype Partial HLA Matching Durability and potency Expansion, persistence Safet
Slide 12: Atara's Allogeneic CAR-T Manufacturing Process Leverages Commercial Manufacturing Process for Tab-cel
Atara’s Allogeneic CAR-T Manufacturing Process Leverages Commercial Manufacturing Process for Tab-cel 1 2 3 4 Expose PBMCs to EBV to Coculture PBMCs with Transduce EBV Store CAR T vials, produce EBV presenting B EBV+ BLCL resulting in specific T cells with ready to deliver to cells (EBV+ BLCL) EBV T
Slide 13: Atara's EBV T-Cell Manufacturing Process Creates Defined TCR with EBV Specificity
Atara’s EBV T-Cell Manufacturing Process Creates Defined TCR with EBV Specificity to Help Prevent Off-Target Binding and Alloreactivity Standard Industry Manufacturing Process Atara EBV T-Cell Manufacturing Process EBV+ CD3/CD28 beads B-lymphoblastoid cells Non-specific Physiological activation lead
Slide 14: Atara's CAR T Platform is Supported by Validated Manufacturing Approach
Atara’s CAR T Platform is Supported by Validated Manufacturing Approach Robust Allogeneic T-Cell Manufacturing Platform • Process utilizes natural T-cell biology and avoids need for gene editing • Leverages tab-cel manufacturing process, validated with approval in Europe and the BLA acceptance with
Slide 15: Atara's Allogeneic CAR T Cell Programs Incorporate Clinically Validated Technologies
Atara’s Allogeneic CAR T Cell Programs Incorporate Clinically Validated Technologies ATA3219 (CD19 CAR) ATA3431 (CD19/20 CAR) Retained MHC EBV TCR EBV TCR Retained MHC CD19 CD20/ ScFv CD19 1XX ScFv 1XX Signaling Domain Signaling Domain Target: Target: CD19+ B-cell malignancies, CD19/CD20+ B-cell mal
Slide 16: ATA3219 in NHL: Opportunity To Compete With a Differentiated Profile
ATA3219 in NHL: Opportunity To Compete With a Differentiated Profile Given Limitations With Other CD19-Targeted Therapies Unmet Need Despite Approved Auto CAR T Bispecifics & Allo CAR Yet to Deliver Access challenges for Efficacy and safety auto CAR T challenges for bispecifics Only ~20-40% of eligi
Slide 17: ATA3219 in NHL: Potential Best-in-Class Profile Versus Commercial Auto CD19 CAR T Benchmark
ATA3219 in NHL: Potential "Best-in-Class" Profile with Superior In Vivo Persistence & Efficacy Versus Commercial Auto CD19 CAR T Benchmark Less Differentiated ATA3219 Longer Persistence ATA3219 Superior Efficacy T Cells for ATA3219 versus auto CD19 CAR benchmark1 versus auto CD19 CAR benchmark1 CD19
Slide 18: ATA3219 in NHL: Phase 1 Study Designed to Establish Proof-of-Platform
ATA3219 in NHL: Phase 1 Study Designed to Establish “Proof-of- Platform” and Evaluate “Best-in-Class” Potential for Program ATA3219 in NHL: Study Overview FIH study to evaluate platform and enable Study Design: comparison with other • Open-label Phase 1 dose escalation and expansion study – 3-6 pati
Slide 19: Our Experience with Allogeneic T Cells Favorably Positions Atara in the Autoimmune CAR T Field
Our Experience with Allogeneic T Cells Favorably Positions Atara in the Autoimmune CAR T Field Differentiated CAR T with Clinically Platform Validated Features Robust Clinical Transformative Data with Platform Potential in Autoimmune Diseases Operating Experience 19
Slide 20: SLE: High Unmet Need and Opportunity for CAR T Therapy
SLE: High Unmet Need and Opportunity for CAR T Therapy High Unmet Need in Systemic Lupus Erythematosus (SLE) • SLE is a chronic autoimmune inflammatory disease affecting multiple organs, with heterogeneity of clinical symptoms and disease severity making it difficult to treat1 • Unmet needs include
Slide 21: The Goal of CAR T Mediated B-Cell Depletion Is Drug-Free and Long-Term Responses for SLE Patients
The Goal of CAR T Mediated B-Cell Depletion Is Drug-Free and Long-Term Responses for SLE Patients CAR T penetrates deep into tissues and rapidly depletes B- cell depletion pathogenic CD19+ B cells Immunological “reset” and reconstitution of naïve B cells Immune system reconstitution lacking the auto
Slide 22: ATA3219 Is Designed to Have a Best-in-Class CAR T Profile in Multiple Autoimmune Diseases
ATA3219 Is Designed to Have a Best-in-Class CAR T Profile in Multiple Autoimmune Diseases Atara’s Differentiated Potential for Enhanced Efficacy, Allogeneic T-Cell Platform Tolerability and Patient Access IFN-ᵞ TNF-ἀ IL-6 • Partial HLA matching • Off-the-shelf availability 120000 12000 400 simplifie
Slide 23: ATA3219 Shows Comparable Cytotoxic Potency and Favorable Inflammatory Profile
ATA3219 Shows Comparable Cytotoxic Potency and Favorable Inflammatory Profile Versus Autologous CD19 CAR T Benchmark 100 120 % Cytolysis 80 Cell Phenotype 100 Terminal Effector (CD45RO-, CCR7-) %Nalm-6 Cytolysis 60 80 Effector Memory % of CD3 (CD45RO+, CCR7-) CD19-specific 40 Maintained a 60 Central
Slide 24: ATA3219 Mediates Complete B-Cell Depletion Against SLE and Multiple Sclerosis Patient Derived Immune Cells
ATA3219 Mediates Complete B-Cell Depletion Against SLE and Multiple Sclerosis Patient Derived Immune Cells ATA3219 NTD EBV T cells SLE MS A n=3 patients B 120 n=3 patients 120 100 B cell cytolysis (%) 100 B cell cytolysis (%) % Cytolysis 80 80 60 60 Against 40 40 third-party (A) 20 20 SLE and (B) MS
Slide 25: ATA3219 in SLE: Phase 1 Study Investigating Preliminary Safety and Efficacy
ATA3219 in SLE: Phase 1 Study Investigating Preliminary Safety and Efficacy of ATA3219 in SLE FIH study to determine ATA3219 in SLE: Study Overview optimal dose while Study Design: establishing preliminary • Open-label Phase 1 dose escalation and expansion study in adult subjects up to age safety an
Slide 26: ATA3219 Features Support Rationale to Omit Lymphodepletion in Extrarenal SLE Cohort
ATA3219 Features and Characteristics Support Rationale to Omit Lymphodepletion in Extrarenal SLE Cohort EBV T Cell Platform Data Additional Features • αβ T cell: Same T-cell type as proven • Atara platform data: • Retained MHC: Partial HLA matching limits commercial autologous CAR Ts Favorable safet
Slide 27: ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing Toward IND Submission
ATA3431: Off-the-Shelf Allogeneic CD19/CD20 CAR T Program Progressing Toward IND Submission in Q4 2025 Targeting CD19 and CD20 reduces probability of relapse due to Retained CD19 antigen loss, hypothesized to be a major cause of treatment MHC resistance or disease relapse after CD19 CAR T treatment
Slide 28: ATA3431: Greater Anti-Tumor Efficacy vs CD19/CD20 Autologous Benchmark
ATA3431: Compelling Proof-of-Concept and Competitive Profile Greater Anti-Tumor Efficacy vs CD19/CD20 Autologous Benchmark Challenging CD19low / CD20+ Raji model 10 10 ATA3431 100 Tumor Burden (BLI; photon/s) Auto benchmark NTD 10 9 PBS Percent Survival 10 8 50 10 7 10 6 10 5 0 10 20 30 40 50 60 70
Slide 29: Expanded Global Tab-cel Partnership With Pierre Fabre Laboratories
Expanded Global Tab-cel® Partnership With Pierre Fabre Laboratories Pierre Fabre Laboratories license for Atara received ~$27M following tab-cel global development, closing and $20M following the manufacturing and commercialization, positive pre-BLA meeting. Atara also with up to $640M in potential
Slide 30: Tab-cel BLA Accepted With Priority Review and a PDUFA Target Action Date of January 15, 2025
Tab-cel BLA Accepted With Priority Review and a PDUFA Target Action Date of January 15, 2025 The BLA is supported by pivotal and supportive data covering more than 430 patients treated with tab-cel across multiple life-threatening diseases • The latest pivotal ALLELE study data demonstrated a statis
Slide 31: Cash Sufficient to Fund Planned Operations into 2027
Cash, Combined with Certain Anticipated Payments from the Expanded Global Partnership, Sufficient to Fund Planned Operations into 2027 $67.2 million 5.7 million Cash, Cash Equivalents, and Shares Outstanding Short-term Investments as of as of September 30, 2024* September 30, 2024 Nasdaq: ATRA Atara
Slide 32: Thank You
THANK YOU Nasdaq: ATRA ATARA BIO
Atara Biotherapeutics — Q3 2024 Earnings Presentation on 6ix